David Palma: Today we completed accrual for the SABR-COMET-10 trial!
David Palma, Radiation Oncologist and Professor at Western University, shared on X/Twitter:
“We made it! Today we completed accrual for the SABR-COMET-10 trial! As far as I know, it’s the first phase III oligomets trial to complete accrual. A few thoughts below:
This was a team effort, with 15 contributing centres across 5 countries: Canada, Switzerland, Scotland, Australia, and the Netherlands. I think trials like these need motivated centres from around the world to accrue at a reasonable pace.
SABR-COMET-10 was a basket trial, accruing all histologies. We’re often asked why we don’t do histology-specific trials. The answer is that accrual is just too slow and there’s a high risk of failure. If this was colorectal cancer only, for example, it would have taken 20 years.
We should have the results in about 2 years. In the meantime, we’re hopeful that SABR-COMET-3 (led by Robert Anton Olson) will finish in 2024.
Many thanks to the patients who joined, to our Cancer Clinical Research Unit at London Health Sciences Centre for running the trial, and for the support of donors to London Health Sciences Foundation who made it all possible.”
Source: David Palma/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023